Unicycive Therapeutics (UNCY) Current Assets (2020 - 2026)

Unicycive Therapeutics (UNCY) has 7 years of Current Assets data on file, last reported at $63.5 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 132.37% year-over-year to $63.5 million; the trailing twelve-month figure through Mar 2026 stood at $63.5 million (up 132.37% YoY), and the FY2025 full-year result was $49.0 million, up 58.2% from the prior year.
• Current Assets for Q1 2026 stood at $63.5 million, up from $49.0 million in the prior quarter.
• Across five years, Current Assets topped out at $63.5 million in Q1 2026 and bottomed at $2.6 million in Q4 2022.
• The 5-year median for Current Assets is $27.3 million (2025), against an average of $29.7 million.
• Peak annual rise in Current Assets reached 1275.68% in 2022, while the deepest fall reached 85.64% in 2022.
• A 5-year view of Current Assets shows it stood at $2.6 million in 2022, then surged by 406.77% to $13.4 million in 2023, then surged by 130.97% to $30.9 million in 2024, then surged by 58.2% to $49.0 million in 2025, then grew by 29.79% to $63.5 million in 2026.
• The last three Current Assets figures came in at $63.5 million (Q1 2026), $49.0 million (Q4 2025), and $50.3 million (Q3 2025), per Business Quant data.

Peer Comparison